Article thumbnail

Temozolomide in aggressive pituitary adenomas and carcinomas

By Leon D. Ortiz, Luis V. Syro, Bernd W. Scheithauer, Fabio Rotondo, Humberto Uribe, Camilo E. Fadul, Eva Horvath and Kalman Kovacs

Abstract

Temozolomide is an alkylating agent used in the treatment of gliomas and, more recently, aggressive pituitary adenomas and carcinomas. Temozolomide methylates DNA and, thereby, has antitumor effects. O6-methylguanine-DNA methyltransferase, a DNA repair enzyme, removes the alkylating adducts that are induced by temozolomide, thereby counteracting its effects. A Medline search for all of the available publications regarding the use of temozolomide for the treatment of pituitary tumors was performed. To date, 46 cases of adenohypophysial tumors that were treated with temozolomide, including 30 adenomas and 16 carcinomas, have been reported. Eighteen of the 30 (60%) adenomas and 11 of the 16 (69%) carcinomas responded favorably to treatment. One patient with multiple endocrine neoplasia type 1 and an aggressive prolactin-producing adenoma was also treated and demonstrated a good response. No significant complications have been attributed to temozolomide therapy. Thus, temozolomide is an effective treatment for the majority of aggressive adenomas and carcinomas. Evidence indicates that there is an inverse correlation between levels of O6-methylguanine-DNA methyltransferase immunoexpression and therapeutic response. Alternatively, high-level O6-methylguanine-DNA methyltransferase immunoexpression correlates with an unfavorable response. Here, we review the use of temozolomide for treating pituitary neoplasms

Topics: Review
Publisher: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
OAI identifier: oai:pubmedcentral.nih.gov:3328813
Provided by: PubMed Central

Suggested articles

Citations

  1. A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma.
  2. a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma.
  3. A novel use of temozolomide in a patient with malignant prolactinoma.
  4. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
  5. Aggressive silent corticotroph adenoma progressing to pituitary carcinoma. The role of temozolomide therapy. Hormones
  6. (1987). Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo [5,1-d]-1,2,3,5-tetrazin-4(3H)-one
  7. Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf).
  8. (2005). Chemical approaches to the discovery and development of cancer therapies. Nat Rev Cancer.
  9. Clinical relevance of MGMT in the treatment of cancer.
  10. Clinical review: Diagnosis and management of pituitary carcinomas.
  11. Current and future developments in the use of temozolomide for the treatment of brain tumours.
  12. (1998). DNA mismatch repair and O 6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma.
  13. (2009). Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma. Hormones
  14. Failure of temozolomide and conventional doses of pegvisomant to attain biochemical control in a severe case of acromegaly. Pituitary.
  15. High incidence of low O 6-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing’s disease.
  16. (1999). Inactivation of the DNA repair gene O 6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res.
  17. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.
  18. Long-term response of pituitary carcinoma to temozolomide. Report of two cases.
  19. Low O 6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxf).
  20. Management of aggressive pituitary adenomas: current treatment strategies.
  21. (2008). Mechanisms of disease: temozolomide and glioblastoma: look to the future. Nat Clin Pract Oncol.
  22. MGMT gene silencing and benefit from temozolomide in glioblastoma.
  23. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma.
  24. MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy.
  25. MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol.
  26. MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.
  27. O 6-Methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment?
  28. O 6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort.
  29. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.
  30. Pituitary carcinoma: a clinicopathologic study of 15 cases.
  31. Pituitary carcinomas. Front Horm Res.
  32. (1999). Prolactin-producing pituitary adenoma and carcinoma with neuronal components: a metaplastic lesion. Pituitary.
  33. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
  34. Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.
  35. Response to temozolomide in patients with metastatic colorectal cancer with loss of MGMT expression: a new approach in the era of personalized medicine?
  36. (2009). Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res.
  37. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
  38. SOM230 (pasireotide) and temozolomide achieve sustained control of tumour progression and ACTH secretion in pituitary carcinoma with widespread metastases. Exp Clin Endocrinol Diabetes.
  39. (2006). Targeted modulation of MGMT: clinical implications. Clin Cancer Res.
  40. Temozolomide (TemodarH) and capecitabine (XelodaH) treatment of an aggressive corticotroph pituitary tumor.
  41. Temozolomide for corticotroph pituitary adenomas refractory to standard therapy.
  42. Temozolomide for the treatment of metastatic melanoma: a systematic review.
  43. Temozolomide in malignant gliomas: current use and future targets.
  44. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.
  45. (2007). Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol.
  46. Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O 6-methylguanine methyltransferase (MGMT) promoter methylation and expression.
  47. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience.
  48. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy.
  49. Temozolomide-induced shrinkage of a pituitary carcinoma causing Cushing’s disease: report of a case and literature review. Scientific World Journal.
  50. (2006). Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol.
  51. (1998). The role of cytotoxic chemotherapy in the management of aggressive and malignant pituitary tumors.
  52. (2008). Treating an aggressive prolactinoma in a patient with MEN 1: beneficial response to temozolomide. Society for Endocrinology BES; Endocrine Abstracts.
  53. Treatment of Nelson’s syndrome with temozolomide.
  54. Treatment of pituitary neoplasms with temozolomide: a review.
  55. Use of temozolomide in aggressive pituitary tumors: case report.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.